Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
The clinical-stage biopharma stock has rallied more than 70% over the past three months on the back of promising clinical data for its lead drug, Palazestrant.
(CNBC, 2025-10-30T19:25:51Z)